242 related articles for article (PubMed ID: 31171473)
21. Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project.
Avet-Loiseau H; Durie BG; Cavo M; Attal M; Gutierrez N; Haessler J; Goldschmidt H; Hajek R; Lee JH; Sezer O; Barlogie B; Crowley J; Fonseca R; Testoni N; Ross F; Rajkumar SV; Sonneveld P; Lahuerta J; Moreau P; Morgan G;
Leukemia; 2013 Mar; 27(3):711-7. PubMed ID: 23032723
[TBL] [Abstract][Full Text] [Related]
22. Additional-structural-chromosomal aberrations are associated with inferior clinical outcome in patients with hyperdiploid multiple myeloma: a single-institution experience.
Carballo-Zarate AA; Medeiros LJ; Fang L; Shah JJ; Weber DM; Thomas SK; Manasanch EE; Hao S; Shen Q; Orlowski RZ; Lin P; Lu X
Mod Pathol; 2017 Jun; 30(6):843-853. PubMed ID: 28281554
[TBL] [Abstract][Full Text] [Related]
23. Heterogeneity in long-term outcomes for patients with Revised International Staging System stage II, newly diagnosed multiple myeloma.
Schavgoulidze A; Lauwers-Cances V; Perrot A; Cazaubiel T; Chretien ML; Moreau P; Facon T; Leleu X; Karlin L; Stoppa AM; Decaux O; Belhadj K; Arnulf B; Mohty M; Ariette CM; Fohrer-Sonntag C; Lenain P; Marolleau JP; Tiab M; Araujo C; Orsini-Piocelle F; Jaccard A; Roussel M; Benboubker L; Eveillard JR; Dib M; Divoux M; Attal M; Avet-Loiseau H; Corre J
Haematologica; 2023 May; 108(5):1374-1384. PubMed ID: 36172814
[TBL] [Abstract][Full Text] [Related]
24. Outcome of Multiple Myeloma with Chromosome 1q Gain and 1p Deletion after Autologous Hematopoietic Stem Cell Transplantation: Propensity Score Matched Analysis.
Varma A; Sui D; Milton DR; Tang G; Saini N; Hasan O; Mukherjee A; Joseph JJ; Bashir Q; Rondon G; Srour S; Popat UR; Hosing CM; Nieto Y; Kebriaei P; Alousi AM; Ahmed S; Mehta R; Khouri IF; Ahmed H; Iyer S; Weber DM; Thomas SK; Manasanch E; Lee HC; Patel K; Ciurea SO; Shpall EJ; Orlowski RZ; Champlin RE; Qazilbash MH
Biol Blood Marrow Transplant; 2020 Apr; 26(4):665-671. PubMed ID: 31881283
[TBL] [Abstract][Full Text] [Related]
25. Outcomes Among High-Risk and Standard-Risk Multiple Myeloma Patients Treated With High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Transplantation.
Kazmi SM; Nusrat M; Gunaydin H; Cornelison AM; Shah N; Kebriaei P; Nieto Y; Parmar S; Popat UR; Oran B; Shah JJ; Orlowski RZ; Champlin RE; Qazilbash MH; Bashir Q
Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):687-93. PubMed ID: 26361647
[TBL] [Abstract][Full Text] [Related]
26. [Detection of complex chromosomal aberrations in patients with multiple myeloma using multiplex fluorescence in situ hybridization].
Jiang YQ; Chen LJ; Zhu Y; Qiu HR; Wang R; Xu JR; Lu H; Li JY
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2010 Aug; 27(4):441-4. PubMed ID: 20677154
[TBL] [Abstract][Full Text] [Related]
27. Impact of revised International Staging System 2 risk stratification on outcomes of patients with multiple myeloma receiving autologous haematopoietic stem cell transplantation.
Alzahrani K; Pasvolsky O; Wang Z; Milton DR; Tanner MR; Bashir Q; Srour S; Saini N; Lin P; Ramdial J; Nieto Y; Lee HC; Patel KK; Manasanch EE; Kebriaei P; Thomas SK; Weber DM; Orlowski RZ; Shpall EJ; Champlin R; Qazilbash MH
Br J Haematol; 2024 May; 204(5):1944-1952. PubMed ID: 38448009
[TBL] [Abstract][Full Text] [Related]
28. Cytogenetic and molecular aberrations of multiple myeloma patients: a single-center study in Singapore.
Lim AS; Lim TH; See KH; Ng YJ; Tan YM; Choo NS; Lim SX; Yee Y; Lau LC; Tien SL; Sathish K; Tan DC
Chin Med J (Engl); 2013; 126(10):1872-7. PubMed ID: 23673102
[TBL] [Abstract][Full Text] [Related]
29. [Analysis of the efficacy and prognosis on first-line autologous hematopoietic stem cell transplantation of patients with multiple myeloma].
Zou DH; Sui WW; Yi SH; An G; Xu Y; Li ZJ; Li CW; Qi JY; Zhao YZ; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2013 Apr; 34(4):299-303. PubMed ID: 23668200
[TBL] [Abstract][Full Text] [Related]
30. 99mTc-sestamibi imaging and bone marrow karyotyping in the assessment of multiple myeloma and MGUS.
Giovanella L; Taborelli M; Ceriani L; Zucca E; Cavalli F; Delaloye AB
Nucl Med Commun; 2008 Jun; 29(6):535-41. PubMed ID: 18458600
[TBL] [Abstract][Full Text] [Related]
31. Prognostic nomogram for multiple myeloma early relapse after autologous stem cell transplant in the novel agent era.
Zhou H; Jian Y; Du J; Liu J; Zhang Z; Yang G; Wang G; Tian Y; Li Y; Wu Y; Chen W; Fu W; Li J; Gao W
Cancer Med; 2023 Apr; 12(8):9085-9096. PubMed ID: 37021846
[TBL] [Abstract][Full Text] [Related]
32. Diffuse pattern of bone marrow involvement on magnetic resonance imaging is associated with high risk cytogenetics and poor outcome in newly diagnosed, symptomatic patients with multiple myeloma: a single center experience on 228 patients.
Moulopoulos LA; Dimopoulos MA; Kastritis E; Christoulas D; Gkotzamanidou M; Roussou M; Koureas A; Migkou M; Gavriatopoulou M; Eleutherakis-Papaiakovou E; Gika D; Koutoulidis V; Terpos E
Am J Hematol; 2012 Sep; 87(9):861-4. PubMed ID: 22641455
[TBL] [Abstract][Full Text] [Related]
33. Predictive role of interphase cytogenetics for survival of patients with multiple myeloma.
Königsberg R; Zojer N; Ackermann J; Krömer E; Kittler H; Fritz E; Kaufmann H; Nösslinger T; Riedl L; Gisslinger H; Jäger U; Simonitsch I; Heinz R; Ludwig H; Huber H; Drach J
J Clin Oncol; 2000 Feb; 18(4):804-12. PubMed ID: 10673522
[TBL] [Abstract][Full Text] [Related]
34. Retrospective analysis of the efficacy and influencing factors of autologous hematopoietic stem cell transplantation for multiple myeloma.
Zhang BL; Zhou J; Lin QD; Liu YZ; Zhang YL; Gui RR; Song YP; Fang BJ
Artif Organs; 2019 Oct; 43(10):1028-1034. PubMed ID: 30972806
[TBL] [Abstract][Full Text] [Related]
35. Prognostic factors for survival after autologous transplantation: a single centre experience in 133 multiple myeloma patients.
Krejci M; Buchler T; Hajek R; Svobodnik A; Krivanova A; Pour L; Adam Z; Mayer J; Vorlicek J
Bone Marrow Transplant; 2005 Jan; 35(2):159-64. PubMed ID: 15543200
[TBL] [Abstract][Full Text] [Related]
36. Chromosomal abnormalities of young multiple myeloma patients (<45 yr) are not different from those of other age groups and are independent of stage according to the International Staging System.
Sagaster V; Kaufmann H; Odelga V; Ackermann J; Gisslinger H; Rabitsch W; Zojer N; Ludwig H; Nösslinger T; Zielinski C; Drach J
Eur J Haematol; 2007 Mar; 78(3):227-34. PubMed ID: 17253972
[TBL] [Abstract][Full Text] [Related]
37. LDH is an adverse prognostic factor independent of ISS in transplant-eligible myeloma patients receiving bortezomib-based induction regimens.
Chim CS; Sim J; Tam S; Tse E; Lie AK; Kwong YL
Eur J Haematol; 2015 Apr; 94(4):330-5. PubMed ID: 25135740
[TBL] [Abstract][Full Text] [Related]
38. [Cytogenetic abnormalities of 50 MDS patients by FISH detection and conventional karyotype analysis].
Gao DG; Li BT; Zhou LN; Chen H; Zhang B
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Oct; 21(5):1190-4. PubMed ID: 24156432
[TBL] [Abstract][Full Text] [Related]
39. [Influence of the number of high-risk cytogenetic abnormalities on the clinical characteristics and prognosis in 360 patients with newly diagnosed multiple myeloma].
Chen Z; Xia Y; Guo R; Zhang R; Qiu HR; Jin YY; Li JY; Chen LJ
Zhonghua Xue Ye Xue Za Zhi; 2022 May; 43(5):408-413. PubMed ID: 35680599
[No Abstract] [Full Text] [Related]
40. Complex karyotype determined using conventional cytogenetic analysis is a poor prognostic factor in patients with multiple myeloma.
Uryu H; Mishima Y; Ishihara Y; Shirouchi Y; Yamauchi N; Hirano M; Hirano K; Teramoto Y; Yoshida K; Maruyama D
J Clin Exp Hematop; 2024; 64(1):10-20. PubMed ID: 38538316
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
